Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin?

J Clin Rheumatol. 2018 Oct;24(7):406-409. doi: 10.1097/RHU.0000000000000709.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antinuclear / blood
  • Atorvastatin* / administration & dosage
  • Atorvastatin* / adverse effects
  • Atorvastatin* / immunology
  • Autoantibodies / blood
  • Autoimmunity / drug effects
  • Biopsy / methods
  • Coronary Artery Disease / drug therapy
  • Dermatomyositis* / chemically induced
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / immunology
  • Diagnosis, Differential
  • Drug Substitution / methods*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / classification
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / immunology
  • Middle Aged
  • Muscle Weakness* / diagnosis
  • Muscle Weakness* / etiology
  • Muscle Weakness* / therapy
  • Pravastatin / administration & dosage*
  • Serologic Tests / methods
  • Skin / pathology*
  • Treatment Outcome

Substances

  • Antibodies, Antinuclear
  • Autoantibodies
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Mi-2 antibodies
  • Atorvastatin
  • Pravastatin